CVS Health Corporation (CVS) fair value analysis
S&P 500 · Updated 2026-10-19
CVS price how computed
Forward Fair Value verdict
Fairly valuedCVS is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $86.16
- Sector
- Healthcare
- 12-month range
- $70.08–$110.60
- Market cap
- $110B
- From 52-week high
- -22.1%
- Shares outstanding
- 1.28B
- Rank in Healthcare by discount to fair value
- #59 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
CVS Health Corporation operates as an integrated pharmacy and healthcare company providing prescription medications, over-the-counter products, and health services through its retail pharmacy network. The company operates pharmacy locations and clinics throughout the United States under the CVS brand name.
CVS currently ranks #59 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $110B
- P/E (trailing)
- 11x
- Revenue (TTM)
- $415B
- Net margin
- 1.2%
- EPS (TTM)
- $7.84
- Gross margin
- 14.8%
- Debt / equity
- 0.96
- Revenue growth (3-yr avg)
- 6.1%
- Shares outstanding
- 1.28B
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 58 · neutral
- 50-day average
- $91.72
- 200-day average
- $88.18
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $2.66 per share (4 payments)
- Yield on last price
- 3.09%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-10-22
- Last payment date
- 2026-11-02
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+38.0%)
2026-03 ▲ beat (+16.3%)
2025-12 ▲ beat (+9.0%)
2025-09 ▲ beat (+17.6%)
2025-06 ▲ beat (+24.0%)
2025-03 ▲ beat (+34.7%)
2024-12 ▲ beat (+29.3%)
2024-09 ▼ miss (-25.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 25 buy · 2 hold · 0 sell (27 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $115
- Target vs last price
- +33.5%
What our data shows for CVS
- Our model validated 17 trailing price-to-earnings windows for CVS, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $70.08–$110.60.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CVS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CVS news
TickrTrends' derived news-sentiment signal for CVS is currently leaning positive, computed from recent coverage.
- CVS Health Settles DOJ Opioid Prescription Claims, Stock Ticker CVS Reacts (gurufocus.com, 2026-10-13)
TickrTrends take: CVS Health's settlement of Department of Justice opioid prescription claims represents a resolution of legal liability that had created uncertainty around the company's financial obligations. Given that TickrTrends currently rates CVS as fairly valued, investors should monitor how this settlement affects the company's cash flow and capital allocation priorities in the Healthcare sector. The resolution removes a contingent liability overhang, though valuation-focused readers will want to track the specific financial impact and any changes to CVS's operational metrics in subsequent quarters to assess whether the fairly valued rating remains appropriate. - 10 Best Blue Chip Stocks Under $100 to Buy Now (insidermonkey.com, 2026-10-11)
TickrTrends take: CVS appears in a roundup of blue chip stocks trading below $100, which aligns with TickrTrends' assessment that the stock is fairly valued at its current price. Healthcare investors monitoring valuation metrics should track whether CVS maintains this pricing equilibrium or shifts relative to sector fundamentals and earnings performance. A fairly valued designation suggests limited margin of safety, making execution on operational metrics particularly relevant for those evaluating entry points. - Jim Cramer Breaks Down the Complicated Story Behind CVS Health’s (CVS) Decline (insidermonkey.com, 2026-10-10)
TickrTrends take: CVS Health operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. Given that analyst commentary highlights complexities underlying the company's recent stock performance, investors focused on valuation should monitor whether these complications resolve in ways that might shift the stock from its current fairly valued position. The relationship between operational challenges and share price movement will be relevant for determining whether the current valuation assessment remains appropriate over time.
What people are saying
Follow the CVS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — CVS improved its valuation position this week, moving from an overvalued assessment to fairly valued status. The company's sector discount rank strengthened to number 78 from number 89, indicating better relative value positioning within the healthcare sector.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CVS stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CVS is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is CVS's TickrTrends verdict?
CVS's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does CVS compare to other Healthcare stocks?
CVS ranks #59 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is CVS overbought or oversold?
CVS's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does CVS pay a dividend?
Yes. CVS paid $2.66 per share over the last twelve months (4 payments), a 3.09% yield on TickrTrends' last price. The last ex-dividend date was 2026-10-22.
When does CVS report earnings next?
CVS's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does CVS usually beat earnings estimates?
Over its last 8 reported quarters CVS beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CVS?
Of 27 analysts covering CVS, 25 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $115 (+33.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
CVS vs A · CVS vs ACHC · CVS vs AVAH · CVS vs COR · CVS vs DHR